---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-080185"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:28:50.294303+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics stockholders approve 1-for-20 reverse stock split, 2025 Incentive Plan

## Summary
- Reverse stock split at 1-for-20 ratio approved; effective April 21, 2025; trading on split-adjusted basis April 22 under symbol MCRB.
- 2025 Incentive Award Plan authorized 44,604,870 shares for future awards, amending and restating the 2015 Plan.
- Three Class I directors elected: Dennis A. Ausiello, M.D.; Willard H. Dere, M.D.; Eric D. Shaff.
- Advisory say-on-pay vote passed with 57.9M for vs 32.5M against.
- Proposals to amend certificate to eliminate supermajority voting and clarify share authorization did not pass.

## SEC filing metadata
- accession: 0001193125-25-080185
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312525080185/0001193125-25-080185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312525080185/d935169d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-080185
- JSON: https://secwatch.observer/filing/0001193125-25-080185.json
- Plain text: https://secwatch.observer/filing/0001193125-25-080185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.